Merck has reached a deal to acquire Peloton Therapeutics, and its Phase 3-ready kidney cancer drug, for $1.05 billion. Under the agreement announced Tuesday, Merck (NYSE: MRK) will pay the sum in cash up front. If Peloton’s drug candidates reach the market and hit sales targets, shareholders of privately held Pelton could gain up to […]
Original Article: Merck Preempts Peloton Therapeutics IPO With $1B Acquisition Deal